This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | MicrobiomeTrials
← Back to trials NCT03038672
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Recruiting PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2018-12-21Est. Completion: 2023-05-26
Enrollment target: 54 participantsLocations Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States Mayo Clinic in Arizona, Scottsdale, Arizona, United States Mayo Clinic in Florida, Jacksonville, Florida, United States Moffitt Cancer Center-International Plaza, Tampa, Florida, United States Moffitt Cancer Center - McKinley Campus, Tampa, Florida, United States Moffitt Cancer Center, Tampa, Florida, United States Northside Hospital, Atlanta, Georgia, United States Northwestern University, Chicago, Illinois, United States University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States University of Kansas Clinical Research Center, Fairway, Kansas, United States HaysMed, Hays, Kansas, United States University of Kansas Cancer Center, Kansas City, Kansas, United States Lawrence Memorial Hospital, Lawrence, Kansas, United States The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States Other microbiome trials you might be interested in Large B-Cell Lymphoma With IRF4 Rearrangement Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma Recurrent ALK-Positive Large B-Cell Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Recurrent Grade 3b Follicular Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
Mercy Hospital Pittsburg, Pittsburg, Kansas, United States
Salina Regional Health Center, Salina, Kansas, United States
University of Kansas Health System Saint Francis Campus, Topeka, Kansas, United States
University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
University Health Truman Medical Center, Kansas City, Missouri, United States
University of Kansas Cancer Center - North, Kansas City, Missouri, United States
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
University of Kansas Cancer Center at North Kansas City Hospital, North Kansas City, Missouri, United States
Washington University School of Medicine, St Louis, Missouri, United States
Siteman Cancer Center-South County, St Louis, Missouri, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States Recurrent Intravascular Large B-Cell Lymphoma
Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Refractory ALK-Positive Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory Grade 3b Follicular Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
Refractory Intravascular Large B-Cell Lymphoma
Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
Refractory Primary Mediastinal Large B-Cell Lymphoma
Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen r…
Scottsdale, United States Est. completion Jun 10, 2027
CD30-Positive Diffuse Large B-Cell Lymphoma Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type Anaplastic Large Cell Lymphoma, ALK-Positive Peripheral T-cell Lymphoma Anaplastic Large Cell Lymphoma, ALK-negative Non-Hodgkin Lymphoma Hodgkin Lymphoma
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or class…
Houston, United States Est. completion Jul 27, 2028